Results 91 to 100 of about 34,807 (281)

Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review

open access: yes, 2021
Dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban are direct oral anticoagulants (DOACs). Their inter-individual variability in pharmacodynamics and pharmacokinetics (transport and metabolism) is high, and could result from genetic ...
Thibault Cousin   +13 more
core   +1 more source

CYP2D6‐Guided Opioid Therapy for Chronic Pain: A Multi‐Center Pragmatic Randomized Controlled Trial

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The analgesic effectiveness of several opioids depends on CYP2D6‐mediated metabolism to more active opioid receptor agonists. CYP2D6 activity is impacted by genetic variability and medications that inhibit CYP2D6. We conducted a pragmatic, multi‐center, randomized, controlled trial to determine whether CYP2D6‐guided opioid prescribing improves chronic ...
Todd C. Skaar   +255 more
wiley   +1 more source

UHPLC–MS/MS Method for the Simultaneous Quantification of 12 Antiretroviral Drugs in Human Plasma Using Dried Sample Spot Devices: Development, Validation, and Stability Evaluation

open access: yesPharmaceutics
Background/Objectives: In several contexts, Dried Sample Spot Devices (DSSDs) offer a convenient and safe alternative for sampling, storage, and shipment, allowing the transport and storage of biological samples at room temperature, reducing shipment ...
Sara Soloperto   +12 more
doaj   +1 more source

Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development

open access: yesBioTechniques, 2005
Pharmacogenetics and pharmacogenomics are keys to the success of personalized medicine, prescribing drugs based on a patien's individual genetic and biological profile.
Li Yan, Robert A. Beckman
doaj   +1 more source

Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in CYP2C19‐Genotyped Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Escitalopram is a frequently prescribed antidepressant drug. CYP2C19 genotype is a major determinant of escitalopram metabolism and treatment outcome. However, real‐life studies show a high degree of genotype–phenotype mismatch in escitalopram metabolism.
Kristine Hole   +3 more
wiley   +1 more source

Respondents knowledge about pharmacogenetics (n = 617).

open access: yes, 2018
Respondents knowledge about pharmacogenetics (n = 617).
Abdullah Albassam (5721110)   +4 more
core   +1 more source

Pharmacogenetics and personalized medicine

open access: yesSaúde & Tecnologia, 2016
Pharmacogenetics aims to identify genetic differences between individuals that may influence the response to drug therapy, improving their effectiveness and safety. Associated with the pharmacogenetics emerges ‘personalized medicine’.
Miguel Brito
doaj   +1 more source

Knowledge of Pharmacogenetics among Healthcare Professionals and Faculty Members of Health Training Institutions in Ghana [PDF]

open access: yes, 2015
Background: Pharmacogenetics has a potential for optimizing drug response and identifying risk of toxicity for patients. Pharmacogenetics knowledge of healthcare professionals and the unmet need for pharmacogenetics education in health training ...
Addy, BS, Dzudzor, B, Kudzi, W
core   +1 more source

Dihydropyrimidine Dehydrogenase Genotype–Phenotype Correlations in Plasma and Peripheral Blood Mononuclear Cells

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The chemotherapeutic 5‐fluorouracil (5‐FU) is commonly used to treat solid tumors, especially colorectal cancer. Deleterious variants in DPYD, which encodes dihydropyrimidine dehydrogenase (DPD), are strongly associated with severe and potentially lethal 5‐FU toxicity.
Brianna M. Bembenek   +4 more
wiley   +1 more source

Overview of Regulatory Guidelines Related to Methods and Models for Small Populations

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
This paper provides an overview of approaches and related guidelines from the EMA, FDA, and ICH that are relevant for obtaining clinical evidence for small populations to support regulatory decision making. The approaches are grouped into three categories: (1) maximizing the attainable sample size, (2) adapting the trial design to deal with a small ...
Laurens Sluijterman   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy